A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS)

Objective: Up to 87% of uterine leiomyosarcomas have estrogen receptor positivity. There are no effective adjuvant therapies for LMS. The objective of this study was to determine the efficacy of letrozole in patients with newly diagnosed uterine leiomyosarcoma (uLMS). The primary endpoint of this st...

Full description

Bibliographic Details
Main Authors: Brian M. Slomovitz, Michael C. Taub, Marilyn Huang, Charles Levenback, Robert L. Coleman
Format: Article
Language:English
Published: Elsevier 2019-02-01
Series:Gynecologic Oncology Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578918301048